甲基转移酶样蛋白14与肿瘤

doi:10.3760/cma.j.cn371439-20220511-00092

摘要/Abstract

摘要：

N⁶-甲基腺嘌呤（m⁶A）修饰是最常见的RNA表观遗传修饰,其在恶性肿瘤发生发展过程中扮演重要角色。甲基转移酶样蛋白14（METTL14）是催化m⁶A修饰的主要甲基化酶之一,参与调节RNA剪接、翻译及降解等生物学进程。最新研究表明METTL14不仅通过多种分子机制调控肿瘤生长、侵袭和转移,而且其表达水平与肿瘤患者预后及抗肿瘤治疗效果密切相关。深入了解METTL14在乳腺癌、消化系统肿瘤及泌尿系统肿瘤中的作用机制,有助于为基于m⁶A修饰的肿瘤防治提供新的临床标志物及药物治疗靶点。

关键词: 肿瘤, N⁶-甲基腺嘌呤, 甲基转移酶样蛋白14, 信号通路, 生物标记物

Abstract:

N⁶-methyladenosine （m⁶A） modification, as the most prevalent epigenetic modification of RNA, plays a crucial role in the initiation and development of malignancies. Methyltransferase like protein 14 （METTL14） is a major methylase catalyzing m⁶A modification and regulating biological processes such as RNA splicing, translation and degradation. Recent studies have demonstrated that METTL14 not only regulates the growth, invasion and metastasis of tumors through various molecular mechanisms, but also is closely correlated with the prognosis of tumor patients and clinical efficacy of anti-tumor therapies. In-depth understanding of the mechanism of METTL14 in breast, digestive system and urinary system tumors is helpful to provide new clinical markers and drug targets for the prevention and treatment of tumors based on m⁶A modification.

Key words: Neoplasms, N⁶-methyladenosine, Methyltransferase like protein 14, Signaling pathway, Biomarkers

胡茹, 李东霖, 严雪冰. 甲基转移酶样蛋白14与肿瘤[J]. 国际肿瘤学杂志, 2022, 49(8): 478-483.

Hu Ru, Li Donglin, Yan Xuebing. Methyltransferase like protein 14 and tumor[J]. Journal of International Oncology, 2022, 49(8): 478-483.

参考文献 59

[1]	Liu X, Qin J, Gao T, et al. Analysis of METTL3 and METTL14 in hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(21): 21638-21659. DOI: 10.18632/aging.103959. doi: 10.18632/aging.103959
[2]	Li Y, Ge YZ, Xu L, et al. The potential roles of RNA N⁶-methyladenosine in urological tumors[J]. Front Cell Dev Biol, 2020, 8: 579919. DOI: 10.3389/fcell.2020.579919. doi: 10.3389/fcell.2020.579919
[3]	Gao R, Ye M, Liu B, et al. m⁶A modification: a double-edged sword in tumor development[J]. Front Oncol, 2021, 11: 679367. DOI: 10.3389/fonc.2021.679367. doi: 10.3389/fonc.2021.679367
[4]	Chen C, Guo Y, Guo Y, et al. m⁶A modification in non-coding RNA: the role in cancer drug resistance[J]. Front Oncol, 2021, 11: 746789. DOI: 10.3389/fonc.2021.746789. doi: 10.3389/fonc.2021.746789
[5]	Xu P, Ge R. Roles and drug development of METTL3 (methyltrans-ferase-like 3) in anti-tumor therapy[J]. Eur J Med Chem, 2022, 230: 114118. DOI: 10.1016/j.ejmech.2022.114118. doi: 10.1016/j.ejmech.2022.114118
[6]	Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol, 2022, 15(1): 8. DOI: 10.1186/s13045-022-01224-4. doi: 10.1186/s13045-022-01224-4
[7]	Guan Q, Lin H, Miao L, et al. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer[J]. J Hematol Oncol, 2022, 15(1): 13. DOI: 10.1186/s13045-022-01231-5. doi: 10.1186/s13045-022-01231-5
[8]	Yi D, Wang R, Shi X, et al. METTL14 promotes the migration and invasion of breast cancer cells by modulating N⁶‑methyladenosine and hsa‑miR‑146a‑5p expression[J]. Oncol Rep, 2020, 43(5): 1375-1386. DOI: 10.3892/or.2020.7515. doi: 10.3892/or.2020.7515
[9]	Sun T, Wu Z, Wang X, et al. LNC942 promoting METTL14-mediated m⁶A methylation in breast cancer cell proliferation and progression[J]. Oncogene, 2020, 39(31): 5358-5372. DOI: 10.1038/s41388-020-1338-9. doi: 10.1038/s41388-020-1338-9
[10]	Peng F, Xu J, Cui B, et al. Oncogenic AURKA-enhanced N⁶-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells[J]. Cell Res, 2021, 31(3): 345-361. DOI: 10.1038/s41422-020-00397-2. doi: 10.1038/s41422-020-00397-2
[11]	Xiao H, Fan X, Zhang R, et al. Upregulated N⁶-methyladenosine RNA in peripheral blood: potential diagnostic biomarker for breast cancer[J]. Cancer Res Treat, 2021, 53(2): 399-408. DOI: 10.4143/crt.2020.870. doi: 10.4143/crt.2020.870 pmid: 33138349
[12]	Gong PJ, Shao YC, Yang Y, et al. Analysis of N⁶-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer[J]. Front Oncol, 2020, 10: 578963. DOI: 10.3389/fonc.2020.578963. doi: 10.3389/fonc.2020.578963
[13]	Zhao C, Ling X, Xia Y, et al. LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m⁶A modification of miR-375 by METTL14 through DNA methylation[J]. Cancer Gene Ther, 2022, 29(7):1043-1055. DOI: 10.1038/s41417-021-00390-w. doi: 10.1038/s41417-021-00390-w
[14]	Dong XF, Wang Y, Huang BF, et al. Downregulated METTL14 expression correlates with breast cancer tumor grade and molecular classification[J]. Biomed Res Int, 2020, 2020: 8823270. DOI: 10.1155/2020/8823270. doi: 10.1155/2020/8823270
[15]	Wu L, Wu D, Ning J, et al. Changes of N⁶-methyladenosine modulators promote breast cancer progression[J]. BMC Cancer, 2019, 19(1): 326. DOI: 10.1186/s12885-019-5538-z. doi: 10.1186/s12885-019-5538-z
[16]	Wang S, Zou X, Chen Y, et al. Effect of N⁶-methyladenosine regulators on progression and prognosis of triple-negative breast cancer[J]. Front Genet, 2021, 11: 580036. DOI: 10.3389/fgene.2020.580036. doi: 10.3389/fgene.2020.580036
[17]	Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶-methyladenosine-dependent primary microRNA processing[J]. Hepatology, 2017, 65(2): 529-543. DOI: 10.1002/hep.28885. doi: 10.1002/hep.28885
[18]	Du L, Li Y, Kang M, et al. USP48 is upregulated by Mettl14 to attenuate hepatocellular carcinoma via regulating SIRT6 stabilization[J]. Cancer Res, 2021, 81(14): 3822-3834. DOI: 10.1158/0008-5472.CAN-20-4163. doi: 10.1158/0008-5472.CAN-20-4163
[19]	Shi Y, Zhuang Y, Zhang J, et al. METTL 14 inhibits hepatocellular carcinoma metastasis through regulating EGFR/PI3K/AKT signaling pathway in an m⁶A-dependent manner[J]. Cancer Manag Res, 2020, 12: 13173-13184. DOI: 10.2147/CMAR.S286275. doi: 10.2147/CMAR.S286275
[20]	Ghazi T, Nagiah S, Chuturgoon AA. Fusaric acid decreases p53 expression by altering promoter methylation and m⁶A RNA methylation in human hepatocellular carcinoma (HepG2) cells[J]. Epigenetics, 2021, 16(1): 79-91. DOI: 10.1080/15592294.2020.1788324. doi: 10.1080/15592294.2020.1788324
[21]	周腾飞, 任子夫, 陈超爽. METTL14在肝细胞癌中的表达及临床意义[J]. 南方医科大学学报, 2020, 40(4): 567-572. DOI: 10.12122/j.issn.1673-4254.2020.04.19. doi: 10.12122/j.issn.1673-4254.2020.04.19
[22]	Wu X, Zhang X, Tao L, et al. Prognostic value of an m⁶A RNA methylation regulator-based signature in patients with hepatocellular carcinoma[J]. Biomed Res Int, 2020, 2020: 2053902. DOI: 10.1155/2020/2053902. doi: 10.1155/2020/2053902
[23]	Fan Z, Yang G, Zhang W, et al. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11[J]. J Cell Mol Med, 2021, 25(21): 10197-10212. DOI: 10.1111/jcmm.16957. doi: 10.1111/jcmm.16957
[24]	Liu X, Xiao M, Zhang L, et al. The m⁶A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway[J]. J Clin Lab Anal, 2021, 35(3): e23655. DOI: 10.1002/jcla.23655. doi: 10.1002/jcla.23655
[25]	Yao Q, He L, Gao X, et al. The m⁶A methyltransferase METTL14-mediated N⁶-methyladenosine modification of PTEN mRNA inhi-bits tumor growth and metastasis in stomach adenocarcinoma[J]. Front Oncol, 2021, 11: 699749. DOI: 10.3389/fonc.2021.699749. doi: 10.3389/fonc.2021.699749
[26]	Fan HN, Chen ZY, Chen XY, et al. METTL14-mediated m⁶A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis[J]. Mol Cancer, 2022, 21(1): 51. DOI: 10.1186/s12943-022-01521-z. doi: 10.1186/s12943-022-01521-z
[27]	Hu N, Ji H. N⁶-methyladenosine (m⁶A)-mediated up-regulation of long noncoding RNA LINC01320 promotes the proliferation, migration, and invasion of gastric cancer via miR495-5p/RAB19 axis[J]. Bioengineered, 2021, 12(1): 4081-4091. DOI: 10.1080/21655979.2021.1953210. doi: 10.1080/21655979.2021.1953210
[28]	Shimura T, Kandimalla R, Okugawa Y, et al. Novel evidence for m⁶A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer[J]. Br J Cancer, 2022, 126(2): 228-237. DOI: 10.1038/s41416-021-01581-w. doi: 10.1038/s41416-021-01581-w
[29]	Kong F, Liu X, Zhou Y, et al. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells[J]. Int J Biochem Cell Biol, 2020, 122: 105731. DOI: 10.1016/j.biocel.2020.105731. doi: 10.1016/j.biocel.2020.105731
[30]	Zhang C, Ou S, Zhou Y, et al. m⁶A methyltransferase METTL14-mediated upregulation of cytidine deaminase promoting gemcitabine resistance in pancreatic cancer[J]. Front Oncol, 2021, 11: 696371. DOI: 10.3389/fonc.2021.696371. doi: 10.3389/fonc.2021.696371
[31]	Tian J, Zhu Y, Rao M, et al. N⁶-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression[J]. Gut, 2020, 69(12): 2180-2192. DOI: 10.1136/gutjnl-2019-320179. doi: 10.1136/gutjnl-2019-320179
[32]	Wang M, Liu J, Zhao Y, et al. Upregulation of METTL14 me-diates the elevation of PERP mRNA N⁶ adenosine methylation promoting the growth and metastasis of pancreatic cancer[J]. Mol Cancer, 2020, 19(1): 130. DOI: 10.1186/s12943-020-01249-8. doi: 10.1186/s12943-020-01249-8 pmid: 32843065
[33]	Chen S, Yang C, Wang ZW, et al. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer[J]. J Hematol Oncol, 2021, 14(1): 60. DOI: 10.1186/s13045-021-01072-8. doi: 10.1186/s13045-021-01072-8
[34]	Liu X, Liu L, Dong Z, et al. Expression patterns and prognostic value of m⁶A-related genes in colorectal cancer[J]. Am J Transl Res, 2019, 11(7): 3972-3991.
[35]	Chen X, Xu M, Xu X, et al. METTL14 suppresses CRC progression via regulating N⁶-methyladenosine-dependent primary miR-375 processing[J]. Mol Ther, 2020, 28(2): 599-612. DOI: 10.1016/j.ymthe.2019.11.016. doi: 10.1016/j.ymthe.2019.11.016
[36]	Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Mol Cancer, 2020, 19(1): 46. DOI: 10.1186/s12943-020-1146-4. doi: 10.1186/s12943-020-1146-4
[37]	Chen X, Xu M, Xu X, et al. METTL14-mediated N⁶-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer[J]. Mol Cancer, 2020, 19(1): 106. DOI: 10.1186/s12943-020-01220-7. doi: 10.1186/s12943-020-01220-7
[38]	Wang S, Gan M, Chen C, et al. Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N⁶-methyladenosine methylation through methyltransferase-like 14[J]. Cancer Sci, 2021, 112(8): 3243-3254. DOI: 10.1111/cas.15011. doi: 10.1111/cas.15011
[39]	Wang H, Wei W, Zhang ZY, et al. TCF4 and HuR mediated-METTL14 suppresses dissemination of colorectal cancer via N⁶-methyladenosine-dependent silencing of ARRDC4[J]. Cell Death Dis, 2021, 13(1): 3. DOI: 10.1038/s41419-021-04459-0. doi: 10.1038/s41419-021-04459-0 pmid: 34916487
[40]	Dong L, Chen C, Zhang Y, et al. The loss of RNA N⁶-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8⁺ T cell dysfunction and tumor growth[J]. Cancer Cell, 2021, 39(7): 945-957.e10. DOI: 10.1016/j.ccell.2021.04.016. doi: 10.1016/j.ccell.2021.04.016
[41]	Wang L, Hui H, Agrawal K, et al. m⁶A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy[J]. EMBO J, 2020, 39(20): e104514. DOI: 10.15252/embj.2020104514. doi: 10.15252/embj.2020104514
[42]	Luo M, Huang Z, Yang X, et al. PHLDB2 mediates cetuximab resistance via interacting with EGFR in latent metastasis of colorectal cancer[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(4): 1223-1242. DOI: 10.1016/j.jcmgh.2021.12.011. doi: 10.1016/j.jcmgh.2021.12.011
[43]	Guimarães-Teixeira C, Lobo J, Miranda-Gonçalves V, et al. Downregulation of m⁶A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness[J]. Mol Oncol, 2022, 16(9): 1841-1856. DOI: 10.1002/1878-0261.13181. doi: 10.1002/1878-0261.13181
[44]	Gu C, Wang Z, Zhou N, et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N⁶-methyladenosine of Notch1[J]. Mol Cancer, 2019, 18(1): 168. DOI: 10.1186/s12943-019-1084-1. doi: 10.1186/s12943-019-1084-1
[45]	Zhang N, Hua X, Tu H, et al. Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells[J]. Cancer Lett, 2021, 520: 400-408. DOI: 10.1016/j.canlet.2021.07.041. doi: 10.1016/j.canlet.2021.07.041 pmid: 34332039
[46]	Wei W, Sun J, Zhang H, et al. Circ0008399 interaction with WTAP promotes assembly and activity of the m⁶A methyltransfe-rase complex and promotes cisplatin resistance in bladder cancer[J]. Cancer Res, 2021, 81(24): 6142-6156. DOI: 10.1158/0008-5472.CAN-21-1518. doi: 10.1158/0008-5472.CAN-21-1518
[47]	Gong D, Zhang J, Chen Y, et al. The m⁶A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca²⁺nflux modulating ERK1/2 phosphorylation and MMP9 signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 233. DOI: 10.1186/s13046-019-1223-y. doi: 10.1186/s13046-019-1223-y
[48]	Wang Q, Zhang H, Chen Q, et al. Identification of METTL14 in kidney renal clear cell carcinoma using bioinformatics analysis[J]. Dis Markers, 2019, 2019: 5648783. DOI: 10.1155/2019/5648783. doi: 10.1155/2019/5648783
[49]	Wang J, Zhang C, He W, et al. Effect of m⁶A RNA methylation regulators on malignant progression and prognosis in renal clear cell carcinoma[J]. Front Oncol, 2020, 10: 3. DOI: 10.3389/fonc.2020.00003. doi: 10.3389/fonc.2020.00003
[50]	Wang Y, Cong R, Liu S, et al. Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma[J]. Cancer Cell Int, 2021, 21(1): 46. DOI: 10.1186/s12935-020-01738-2. doi: 10.1186/s12935-020-01738-2 pmid: 33430867
[51]	Zhang C, Chen L, Liu Y, et al. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma[J]. The-ranostics, 2021, 11(8): 3676-3693. DOI: 10.7150/thno.55424. doi: 10.7150/thno.55424
[52]	Liu T, Wang H, Fu Z, et al. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1[J]. Cancer Sci, 2022, 113(2): 446-458. DOI: 10.1111/cas.15212. doi: 10.1111/cas.15212
[53]	Shen D, Ding L, Lu Z, et al. METTL14-mediated Lnc-LSG1 m⁶A modification inhibits clear cell renal cell carcinoma metastasis via regulating ESRP2 ubiquitination[J]. Mol Ther Nucleic Acids, 2022, 27: 547-561. DOI: 10.1016/j.omtn.2021.12.024. doi: 10.1016/j.omtn.2021.12.024
[54]	Xu T, Gao S, Ruan H, et al. METTL14 Acts as a potential regulator of tumor immune and progression in clear cell renal cell carcinoma[J]. Front Genet, 2021, 12: 609174. DOI: 10.3389/fgene.2021.609174. doi: 10.3389/fgene.2021.609174
[55]	Ji G, Huang C, He S, et al. Comprehensive analysis of m⁶A regulators prognostic value in prostate cancer[J]. Aging (Albany NY), 2020, 12(14): 14863-14884. DOI: 10.18632/aging.103549. doi: 10.18632/aging.103549
[56]	Liu Z, Zhong J, Zeng J, et al. Characterization of the m⁶A-associated tumor immune microenvironment in prostate cancer to aid immunotherapy[J]. Front Immunol, 2021, 12: 735170. DOI: 10.3389/fimmu.2021.735170. doi: 10.3389/fimmu.2021.735170
[57]	Wu Q, Xie X, Huang Y, et al. N⁶-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer[J]. J Cancer, 2021, 12(3): 682-692. DOI: 10.7150/jca.46379. doi: 10.7150/jca.46379
[58]	Feng D, Shi X, Xiong Q, et al. A ferroptosis-related gene prognostic index associated with biochemical recurrence and radiation resistance for patients with prostate cancer undergoing radical radiotherapy[J]. Front Cell Dev Biol, 2022, 10: 803766. DOI: 10.3389/fcell.2022.803766. doi: 10.3389/fcell.2022.803766
[59]	Yuan Y, Du Y, Wang L, et al. The m⁶A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation[J]. J Cancer, 2020, 11(12): 3588-3595. DOI: 10.7150/jca.42338. doi: 10.7150/jca.42338 pmid: 32284755